Skip to content

Effect of a Symbiotic Drink on the Microbiota

Nutritional Intervention Study to Evaluate the Effect of a Symbiotic Drink on the Microbiota and Different Nutritional Markers in Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06626997
Acronym
KOMFIBRA
Enrollment
60
Registered
2024-10-04
Start date
2024-01-22
Completion date
2024-06-28
Last updated
2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Kombucha, Microbiota

Brief summary

This study is expected to involve 60 volunteers who will be recruited by IMDEA-Alimentación and randomly assigned between a study group (which will consume the fermented drink) and a control group, which will consume a drink with similar characteristics, but without the presence of bioactive components.

Detailed description

At the beginning of the trial, you will have an interview (screening visit) with a dietician-nutritionist who will explain the entire procedure to you and answer any questions you may have about it. If it is confirmed that you meet the criteria to participate in the study, after your assent and informed consent have been obtained, you will be able to do so. At the first visit, you will be assigned a code by a random method (computerized) and neither you nor the researcher will know whether you are receiving the enriched product or the traditional one that will be used as a control.

Interventions

DIETARY_SUPPLEMENTKombucha tea

During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory. You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2).

Sponsors

IMDEA Food
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Masking description

The study will be masked by using identical packaging for both the study group and the control group (placebo), which participants will consume at home or at their mealtimes during the 6 weeks of the intervention. The researchers themselves will administer the product (with identical external appearance for both groups) individually to each participant.

Intervention model description

Prospective, parallel, randomized 6-week nutritional intervention study.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men and women ≥ 18 years of age. * Caucasian ethnicity * Adequate level of culture and understanding of the clinical study. * Agree to voluntarily participate in the study and give written informed consent.

Exclusion criteria

* Subjects with dementia, mental illness or decreased cognitive function that prevents the study from being carried out. * Subjects with serious diseases (liver, kidney, immunosuppressed, etc.). * BMI ≥ 30 kg/m2, pregnant or breastfeeding women. * Presence of immunological pathologies, gallstones, gastric ulcer or coagulation problems. * Presence of any other specific pathology that contraindicates the intake of dietary supplements, specifically inulin and probiotics (diverticulitis, etc.). * Subjects who are undergoing antibiotic treatment or consuming probiotic supplements. * Subjects who are undergoing pharmacological treatment for weight loss. * Subjects who refuse to follow the guidelines for healthy eating or the consumption of the study drink in the indicated guidelines. * Any other

Design outcomes

Primary

MeasureTime frameDescription
Relative abundance of the gut microbial species6 weeksAnalyze the variations in the relative abundance of the microbial species present, including taxonomic identification, diversity analysis, and phylogenetic composition.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026